Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Chen MY, Juengpanich S, Hu JH, Topatana W, Cao JS, Tong CH, et al. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma. World J Gastroenterol. 2020;26(10):1042–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–16.

Article  CAS  PubMed  Google Scholar 

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66.

Article  PubMed  PubMed Central  Google Scholar 

Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, et al. Hepatic function during repeated TACE procedures and prognosis after introducing Sorafenib in patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Dig Dis. 2017;35(6):602–10.

Article  PubMed  Google Scholar 

Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36(1):100–7.

Article  CAS  PubMed  Google Scholar 

Liu B, Teng F, Ding G. Prognostic model for patients receiving arterial-embolization for hepatocellular carcinoma: issues to consider. Liver Int. 2016;36(2):311.

Article  CAS  PubMed  Google Scholar 

Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59(4):1415–26.

Article  CAS  PubMed  Google Scholar 

Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64(2):516–22.

Article  CAS  PubMed  Google Scholar 

Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2021;79(1):36–46.

Article  PubMed  Google Scholar 

Tian Y, Zhang M, Liu LX, Wang ZC, Liu B, Huang Y, et al. Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis. Front Immunol. 2024;15:1400744.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang X, Chen R, Jiao Z, Shen B, Shuai Z. HSCs-derived exosomes regulate the levels of inflammatory cytokines in HIBECs through mir-122-5p mediated p38 MAPK signaling pathway. Genomics. 2024;116(2):110795.

Article  CAS  PubMed  Google Scholar 

Gramantieri L, Fornari F, Giovannini C, Trerè D. MicroRNAs at the crossroad between immunoediting and oncogenic drivers in hepatocellular carcinoma. Biomolecules. 2022;12(7).

El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: detrimental and favorable aspects of key performers. Pathol Res Pract. 2022;233:153886.

Article  CAS  PubMed  Google Scholar 

Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68–77.

PubMed  Google Scholar 

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991–5.

CAS  PubMed  Google Scholar 

Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boldanova T, Fucile G, Vosshenrich J, Suslov A, Ercan C, Coto-Llerena M, et al. Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. Cell Rep Med. 2021;2(11):100444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyu H, Wang S, Huang J, Wang B, He Z, Liu B. Survivin-targeting mir-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett. 2018;420:97–108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130.

Article  PubMed  PubMed Central  Google Scholar 

Singh P, Toom S, Avula A, Kumar V, Rahma OE. The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:11–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puentes-Pardo JD, Moreno-SanJuan S, Carazo Á, León J. Heme oxygenase-1 in gastrointestinal tract health and disease. Antioxidants (Basel). 2020;9(12).

Hjortsø MD, Andersen MH. The expression, function and targeting of haem oxygenase-1 in cancer. Curr Cancer Drug Targets. 2014;14(4):337–47.

Article  PubMed  Google Scholar 

Luu Hoang KN, Anstee JE, Arnold JN. The diverse roles of heme oxygenase-1 in tumor progression. Front Immunol. 2021;12:658315.

Article  PubMed  PubMed Central  Google Scholar 

Sass G, Leukel P, Schmitz V, Raskopf E, Ocker M, Neureiter D, et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer. 2008;123(6):1269–77.

Article  CAS  PubMed  Google Scholar 

Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, et al. Donafenib and GSK-J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression. Adv Sci (Weinh). 2023;10(22):e2206798.

Article  PubMed  Google Scholar 

Feng Z, Cao K, Sun H, Liu X. SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis. Apoptosis. 2024;29(9–10):1723–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou C, Zou C, Cheng W, Li Q, Han Z, Wang X, et al. Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway. Oncol Rep. 2016;36(5):2715–22.

Article  CAS  PubMed  Google Scholar 

Nitti M, Ivaldo C, Traverso N, Furfaro AL. Clinical significance of heme oxygenase 1 in tumor progression. Antioxidants (Basel). 2021;10(5).

Cheng ML, Lu YF, Chen H, Shen ZY, Liu J. Liver expression of Nrf2-related genes in different liver diseases. Hepatobiliary Pancreat Dis Int. 2015;14(5):485–91.

Article  CAS  PubMed  Google Scholar 

Hammoutene A, Laouirem S, Albuquerque M, Colnot N, Brzustowski A, Valla D, et al. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023;5(10):100845.

Article  PubMed  PubMed Central  Google Scholar 

Hassan M, Ibrahim MA, Hafez HM, Mohamed MZ, Zenhom NM, Abd Elghany HM. Role of Nrf2/HO-1 and PI3K/Akt genes in the hepatoprotective effect of cilostazol. Curr Clin Pharmacol. 2019;14(1):61–7.

Article  CAS  PubMed  Google Scholar 

Basic M, Thiyagarajah K, Glitscher M, Schollmeier A, Wu Q, Görgülü E, et al. Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg-negative patient isolates reflects an evolutionary process. Liver Int. 2024;44(10):2773–92.

Article  CAS